Latest Summaries
FDA Approves Treatment for Chronic Graft Versus Host Disease
Corey Cutler, MD, Director of Adult Stem Cell…Global Cancer Burden Among Men: Disparities and Projections
Ryan Motte, PharmD, Clinical Pharmacist at Shields Health…Advancements in the Treatment of Myasthenia Gravis
Henry J. Kaminski, MD, Professor of Medicine at…Arginine Vasopressin (AVP) Deficiency
Arginine vasopressin (AVP) deficiency is a rare neuroendocrine…Addressing the Challenges of Hypercortisolism in Cushing’s Syndrome
David Katz, PhD, Chief Scientific Officer and Founder…Pegcetacoplan in Patients With C3G and Primary IC-MPGN
Carla Nester, MD, professor at the University of…Treatment Effect on Patient Pain and Quality of Life in Neuromyelitis Optica
Bruce Cree, MD, PhD, Professor of Clinical Neurology…Patient Perspective: Journey to a Myasthenia Gravis Diagnosis
Anita Longoria, a patient advocate, discusses her journey…Long-Term Data Testing Treatment in Patients With Thyroid Eye Disease
Prem Subramanian, MD, PhD, Professor of Ophthalmology at…Expanded Label of Treatment for Primary Immunodeficiencies
Richard Wasserman, MD, PhD, Medical Director of Pediatric…Long-Term Data of Trofinetide in Patients With Rett Syndrome
Ponni Subbiah, MD, Senior Vice President of Acadia,…Accelerated Approval for IgA Nephropathy Treatment
Dana Rizk, MD, Professor of Medicine at the…Gene Therapy Long-Term Data for Retinal Dystrophy
Stephen Russell, MD, Professor of Ophthalmology and Visual…Navigating Diagnosis and Treatment for Primary Biliary Cholangitis: The Integral Role of the Patient Voice
Dr. Sonal Kumar, an Assistant Professor of Medicine,…Long-Term Data of Trofinetide in Patients With Rett Syndrome
Alan Percy, MD, Professor of Pediatrics, Neurology, Neurobiology,…Erdheim-Chester Disease
Erdheim-Chester disease (ECD) is a rare condition affecting…Oral Octreotide in Patients With Acromegaly
Maria Fleseriu, MD, Director of the Pituitary Center…Clinical Trial Evaluating Investigational AVB-101 in Patients With FTD
James “Brad” Elder, MD, Director of Neurosurgical Oncology…Supplemental Data on the Efficacy of Fenfluramine to Treat Dravet Syndrome-Associated Seizures
Kelly Knupp, MD, Associate Professor of Pediatrics and…Pathophysiology of AL Amyloidosis and the Mechanism of Action of Investigational Drug
Hideki Garren, MD, PhD, Chief Medical Officer for…Type 1 Galactosemia: Significant Unmet Need, Lifelong Complications, and Current Management
Type 1 galactosemia is a rare genetic disease that can be life-threatening in newborns and can lead to lifelong cognitive, neurological, and speech complications, as well as primary ovarian insufficiency in girls and women.
Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders.
Myasthenia Gravis and the Complement System
James F Howard Jr, MD, Professor of Neurology, Medicine & Allied Health at The University of North Carolina at Chapel Hill, highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease.
New Guidance to Diagnose and Treat Tumor-induced Osteomalacia (TIO)
Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose and treat tumor induced osteomalacia (TIO) based on the recently published global guidance document in the Journal of Internal Medicine.
Learn About WHIM Syndrome
WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with neutropenia that typically presents in childhood or adolescence, predominantly caused by pathogenic variants in the CXCR4 chemokine receptor gene.
WHIM Syndrome Learning Center
WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with severe neutropenia that affects all ages. However, due to the heterogeneous presentation of the disease, coupled with lack of awareness of the condition, the diagnosis may be delayed, sometimes even into adulthood.
Tenosynovial Giant Cell Tumors (TGCT) Explained
Richard F. Riedel, MD, Medical Oncologist, Duke Health, discusses tyenosynovial giant cell tumors (TGCT)
Assessing, Monitoring, and Managing Respiratory Involvement in Lysosomal Disorders
Ozlem Gore-Alpan, MD of LDRTC and John Bach, MD, Professor of Neurology at Rutgers School of Medicine discuss best practices to manage respiratory complications in persons with lysosomal disorders.
Warm Autoimmune Hemolytic Anemia (wAIHA)
Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current best practices for diagnosing and managing patients with wAIHA.
Managing Cardiomyopathies in Lysosomal Disorders
Ozlem Goker-Alpan, MD, Founder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) and John Jefferies, MD discuss lysomal orders.
Cutaneous T-Cell Lymphoma Learning Center
Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders. It is a rare group of malignancies, with an incidence of 6.4 cases per 1 million people.
Tenosynovial Giant Cell Tumor (TGCT)
Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor involving the joint synovium, bursae, and tendon sheath. These rare tumors are sometimes referred to as giant cell tumor of the tendon sheath (GCT-TS) and/or pigmented villonodular synovitis (PVNS).